Stryker stock price target raised to $410 from $408 at BTIG

Investing.com - BTIG raised its price target on Stryker (NYSE:SYK) to $410 from $408 while maintaining a Buy rating following the company’s third-quarter 2025 results. The new target suggests approximately 11% upside from the current price of $368.98, aligning with the broader analyst sentiment as InvestingPro data shows an average analyst target implying 18% potential upside.

Stryker reported revenue of $6.057 billion for the third quarter, representing a 10.3% year-over-year increase, with 9.5% organic growth. This performance exceeded BTIG’s estimates by 3.7% and slightly surpassed Street expectations by 0.2%, as strength in the Orthopedics segment offset softer performance in MedSurg and Neurotechnology. The quarterly results align with Stryker’s consistent growth trajectory, with InvestingPro data showing 11.36% revenue growth over the last twelve months and a 5-year revenue CAGR of 9%.

The medical technology company posted adjusted earnings per share of $3.19, beating BTIG and Street estimates by 2.1% and 1.8% respectively, despite gross margins and operating margins missing Street expectations by approximately 10 and 20 basis points.

Stryker raised its full-year 2025 guidance, now projecting organic growth of 9.8%-10.2%, up from the previous range of 9.5%-10.0%. The company also narrowed its adjusted earnings per share forecast to $13.50-$13.60, compared to the prior range of $13.40-$13.60.

BTIG noted that management deferred questions about long-term growth, margin trajectory, and new product introductions until Stryker’s upcoming biennial Analyst Day scheduled for November 13. Investors following Stryker may be interested to know that the company has maintained dividend payments for 35 consecutive years and raised its dividend for 15 consecutive years, according to InvestingPro, which offers comprehensive analysis through its Pro Research Reports covering what really matters about Stryker and 1,400+ other top stocks.

In other recent news, Stryker Corporation reported strong performance in its second quarter of 2025, highlighting significant organic sales growth and strategic product innovations. The company has raised its full-year guidance, indicating confidence in continued growth. These developments suggest that Stryker is optimistic about its future performance. This update follows an earnings call where the company detailed its robust financial results. Analysts have been closely watching Stryker’s performance, and the raised guidance is a positive signal for investors. The company’s strategic innovations have played a key role in driving its growth. These recent developments are likely to be of interest to investors monitoring Stryker’s progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.